BioWorld

June 18, 2010

OncoMed Has 'Wnt' in its Sails; Bayer Deal Adds $40M Up Front

For a firm that has yet to reach Phase II with a lead program, OncoMed Pharmaceuticals Inc. has managed some pretty impressive feats in the past few years. (BioWorld Today) Read More

Neurocrine in $235M Deal with Boehringer for GPR119 Agonists

Arginetix, Immune Control Merge Two Corridors in Vascular Space

Aquinox Raises $25M for Blood, Immune Disorders Molecule

EULAR Roundup

Stimuvax Hold Lifted in NSCLC; Oncothyreon, EMD Move Ahead

Stock Movers

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...

DEE-lightful: Praxis’ phase II results allow stock to flex its muscle

BioWorld

Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...